Special Issue

Epidemiology and Treatment of Microbial Infections in Respiratory Diseases

Message from the Guest Editors

Pulmonary infections remain a major global health concern, with a considerable impacts on morbidity, mortality, and healthcare systems, especially in lowresource settings. Accurate and timely epidemiological data are essential for tracking trends, identifying at-risk populations, and informing both clinical and public health responses. At the same time, treatment approaches continue to evolve in response to changes in pathogen profiles, antimicrobial resistance patterns. and advances in clinical care. Despite these developments, challenges remain in achieving optimal outcomes, particularly in the context of increasing multidrug resistance and the complexity of coinfections, especially in critically ill patients requiring treatment in the ICU. This Special Issue welcomes original research and review articles that explore the epidemiology, risk factors, therapeutic strategies, and clinical outcomes of pulmonary infections. Contributions that shed light on infection trends, treatment efficacy, resistance mechanisms, and emerging interventions are especially encouraged.

Guest Editors

Dr. Marija Vukoja

The Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Prof. Dr. Peđa Kovačević

- 1. University Clinical Centre of Republic of Srpska, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina
- 2. Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina

Deadline for manuscript submissions

31 October 2025



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/238379

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

